Stablepharma Limited

Stablepharma Limited is a pioneering biopharmaceutical company dedicated to revolutionizing the delivery of temperature-sensitive pharmaceuticals. With its innovative StablevaX™ technology, Stablepharma aims to eliminate the reliance on the cold chain for vaccine and pharmaceutical distribution, significantly improving global health outcomes. The primary address of Stablepharma is 4 Queen Street, Bath, NE Somerset BA1 1HE, GB, with an additional location at C. de Santiago Grisolia, 2, 28760, Tres Cantos, Madrid, 28760, ES.

Stablepharma's core mission is to enhance the stability and accessibility of vital vaccines, ensuring they can be stored for extended periods at room temperature. By addressing the challenges associated with the cold chain, Stablepharma is committed to reducing vaccine wastage, minimizing CO2 emissions, and improving the overall efficiency of vaccination programs worldwide. Stablepharma is actively developing SPVX02, the world's first fridge-free vaccine for Tetanus and Diphtheria prevention.

Stablepharma's StablevaX™ technology offers an adaptable and extended shelf-life solution, aligning with WHO protocols and contributing to pandemic preparedness. Stablepharma is positioned to make a substantial impact on global healthcare by ensuring that life-saving vaccines reach those who need them most, regardless of logistical challenges. The information will be completed soon with the support of the company’s management. We invite Stablepharma Limited's manager to create a customized and exclusive company showcase and product listing on our platform.